NewAmsterdam Pharma (NAMS) Debt to Equity (2022 - 2025)
Historic Debt to Equity for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $0.06.
- NewAmsterdam Pharma's Debt to Equity rose 2213.06% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.06, marking a year-over-year increase of 2213.06%. This contributed to the annual value of $0.05 for FY2024, which is 1358.53% up from last year.
- Per NewAmsterdam Pharma's latest filing, its Debt to Equity stood at $0.06 for Q3 2025, which was up 2213.06% from $0.03 recorded in Q2 2025.
- Over the past 5 years, NewAmsterdam Pharma's Debt to Equity peaked at $0.08 during Q1 2024, and registered a low of $0.0 during Q2 2023.
- Over the past 4 years, NewAmsterdam Pharma's median Debt to Equity value was $0.05 (recorded in 2024), while the average stood at $0.04.
- In the last 5 years, NewAmsterdam Pharma's Debt to Equity surged by 26954649.33% in 2024 and then crashed by 6230.86% in 2025.
- NewAmsterdam Pharma's Debt to Equity (Quarter) stood at $0.01 in 2022, then surged by 443.34% to $0.04 in 2023, then rose by 13.59% to $0.05 in 2024, then rose by 23.03% to $0.06 in 2025.
- Its Debt to Equity was $0.06 in Q3 2025, compared to $0.03 in Q2 2025 and $0.03 in Q1 2025.